Indication of Adbry (tralokinumab-ldrm) expanded to include patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable.
The FDA has approved an expanded indication for LEO Pharma’s Adbry (tralokinumab-ldrm) for patients 12 to 17 years of age with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable.1 Adbry is a human immunoglobulin G4 monoclonal antibody that specifically binds to human interleukin (IL)-13 and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. Adbry is the first and only biologic FDA-approved for this indication.
“This is an important milestone on our path towards making a fundamental difference for those who need it most. This critical patient group now has access to a much-needed additional treatment option to manage their atopic dermatitis,” Brian Hilberdink, EVP and president, Region North America, LEO Pharma, said in a press release. “We are delighted to be able to offer Adbry, a highly targeted treatment, to both adult and pediatric patients in the US. This debilitating disease can have a particularly strong impact on pediatric patients, who often feel socially isolated because of their condition. We are incredibly proud of the progress we have made to date, and we will continue to work hard to address unmet needs in additional patient populations.”1
In clinical trials, the drug produced significant improvements in itch, sleep interference, anxiety, depression, and overall quality of life among patients 12 to 17 years of age with moderate-to-severe AD.2 The expanded indication is for an initial loading dose of 300 mg followed by 150 mg dose every two weeks for this patient group.
The FDA based its approval for the expanded indication of Adbry on data from the Phase III ECZTRA 6 trial. Investigators evaluated the drug’s efficacy and safety in 289 patients aged 12-17 years with moderate-to-severe AD who were candidates for systemic therapy. Of those enrolled in the trial, 98 patients were administered an initial dose of Adbry 300 mg followed by 150 mg every other week up to week 16.
The study showed that 21% of patients administered Adbry achieved an Investigator’s Global Assessment (IGA) score of 0 or 1 vs. 4% administered placebo. The trial also found that 29% of patients administered Adbry achieved at least a 75% improvement in Eczema Area and Severity Index score (EASI-75) vs. 6% administered placebo.
Further, 23% of patients administered Adbry achieved at least a four-point drop in Adolescent Worst Pruritis Numerical Rating Scale vs. 3% with placebo and a greater proportion of patients administered Adbry achieved at least a 90% improvement in EASI-90 compared to placebo.
“We know the symptoms associated with moderate-to-severe atopic dermatitis can have an impact on pediatric patients, which is why it’s so important to have treatment options with demonstrated efficacy in itch reduction and skin clearance,” said international coordinating investigator for ECZTRA 6, Amy Paller, MD, chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University in Chicago, in a press release. “Clinical trial results that provide this evidence are invaluable to clinicians evaluating the safety and efficacy of treatment options for their pediatric patients.”1
In terms of safety, the drug’s profile was comparable to what has been reported in clinical trials by adults with atopic dermatitis. The most common adverse events reported in adults were upper respiratory tract infections, conjunctivitis, injection site reactions, and eosinophilia.
“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” said Julie Block, president and CEO of the National Eczema Association, said in a press release. “Such advances in the atopic dermatitis treatment landscape provide much-needed hope for pediatric patients seeking a long-term treatment option that could work for them.”1
References
1. LEO Pharma Inc. Announces U.S. FDA approval of Adbry® (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years. LEO Pharma. News release. December 15, 2023. Accessed December 19, 2023. https://www.businesswire.com/news/home/20231215374551/en/LEO-Pharma-Inc.-Announces-U.S.-FDA-approval-of-Adbry%C2%AE-tralokinumab-ldrm-for-the-Treatment-of-Moderate-to-severe-Atopic-Dermatitis-in-Pediatric-Patients-Aged-12-17-Years
2. Soong et al. Tralokinumab treatment substantially improves patient-reported outcomes in adolescents with moderate-to-severe atopic dermatitis at 16 weeks. WSAAI. Feb 6-10, 2022. Maui, HI. Poster Presentation. Accessed December 19, 2023.